Show simple item record

dc.contributor.authorHadinoto, Vey
dc.contributor.authorShapiro, Michael
dc.contributor.authorGreenough, Thomas C.
dc.contributor.authorSullivan, John L.
dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorThorley-Lawson, David A.
dc.date2022-08-11T08:10:12.000
dc.date.accessioned2022-08-23T16:58:58Z
dc.date.available2022-08-23T16:58:58Z
dc.date.issued2008-02-01
dc.date.submitted2012-05-01
dc.identifier.citationBlood. 2008 Feb 1;111(3):1420-7. Epub 2007 Nov 8. <a href="http://dx.doi.org/10.1182/blood-2007-06-093278">Link to article on publisher's site</a>
dc.identifier.issn0006-4971 (Linking)
dc.identifier.doi10.1182/blood-2007-06-093278
dc.identifier.pmid17991806
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43480
dc.description.abstractMemory B cells latently infected with Epstein-Barr virus (mB(Lats)) in the blood disappear rapidly on presentation with acute symptomatic primary infection (acute infectious mononucleosis [AIM]). They undergo a simple exponential decay (average half-life: 7.5 +/- 3.7 days) similar to that of normal memory B cells. The cytotoxic T lymphocyte (CTL) response to immediate early (IE) lytic antigens (CTL(IEs)) also decays over this time period, but no such correlation was observed for the CTL response to lytic or latent antigens or to the levels of virions shed into saliva. We have estimated the average half-life of CTL(IEs) to be 73 (+/- 23) days. We propose that cycles of infection and reactivation occur in the initial stages of infection that produce high levels of mB(Lats) in the circulation. Eventually the immune response arises and minimizes these cycles leaving the high levels of mB(Lats) in the blood to decay through simple memory B-cell homeostasis mechanisms. This triggers the cells to reactivate the virus whereupon most are killed by CTL(IEs) before they can release virus and infect new cells. The release of antigens caused by this large-scale destruction of infected cells may trigger the symptoms of AIM and be a cofactor in other AIM-associated diseases.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17991806&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214734/
dc.subjectAcute Disease
dc.subjectCell Proliferation
dc.subjectCytotoxicity, Immunologic
dc.subjectHerpesvirus 4, Human
dc.subjectImmunologic Memory
dc.subjectInfectious Mononucleosis
dc.subjectTime Factors
dc.subjectImmunology and Infectious Disease
dc.subjectPediatrics
dc.titleOn the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis
dc.typeJournal Article
dc.source.journaltitleBlood
dc.source.volume111
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_immunology/60
dc.identifier.contextkey2814391
html.description.abstract<p>Memory B cells latently infected with Epstein-Barr virus (mB(Lats)) in the blood disappear rapidly on presentation with acute symptomatic primary infection (acute infectious mononucleosis [AIM]). They undergo a simple exponential decay (average half-life: 7.5 +/- 3.7 days) similar to that of normal memory B cells. The cytotoxic T lymphocyte (CTL) response to immediate early (IE) lytic antigens (CTL(IEs)) also decays over this time period, but no such correlation was observed for the CTL response to lytic or latent antigens or to the levels of virions shed into saliva. We have estimated the average half-life of CTL(IEs) to be 73 (+/- 23) days. We propose that cycles of infection and reactivation occur in the initial stages of infection that produce high levels of mB(Lats) in the circulation. Eventually the immune response arises and minimizes these cycles leaving the high levels of mB(Lats) in the blood to decay through simple memory B-cell homeostasis mechanisms. This triggers the cells to reactivate the virus whereupon most are killed by CTL(IEs) before they can release virus and infect new cells. The release of antigens caused by this large-scale destruction of infected cells may trigger the symptoms of AIM and be a cofactor in other AIM-associated diseases.</p>
dc.identifier.submissionpathpeds_immunology/60
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages1420-7


This item appears in the following Collection(s)

Show simple item record